Table 3.

Reported rates of hypogammaglobulinemia after rituximab in children from prospective studies

Study	No. of patients analysed	No. of rituximab courses	Regimen per course mg/m2	Outcome measures		Rate of Hypogammaglobulinemia			Serious infectious episodes
						Overall	Baseline IgG levels
							Normal	Reduced
ANCA-associated vasculitis
Brogan et al., 2022 [43]	25	25	1500	Patient based	Low IgG at 18 months	11/23 (47.8%)	NR	NR	9
Childhood nephrotic syndrome
Guigonis et al., 2008 [44]	22	40	375–1500	Patient based	Low IgG at last follow-upa	8/22 (36.4%)	4/18 (22.2%)	4/4 (100%)	2
Sun et al., 2014 [49]	12	12	375–750	Patient based	Low IgG during rituximab	1/12 (8.3%)	NR	NR	0
Ravani et al., 2020 [54]	30	15	375	Patient based	Low IgG at 6–24 months	0 (0%)	0 (0%)	0 (0%)	NR
Ravani et al., 2021 [57]	30	15	375	Patient based	Low IgG at last follow-upb	8/15 (53.3%)	2/6 (33.3%)	6/9 (67%)	0
Al Salloum et al., 2022 [58]	17	23	750–1500	Patient based	Low IgG at 3 years	1/17 (5.9%)	NR	NR	1
Zhu et al., 2023 [62]	29	29	775–1500	Dose based	Low IgG during rituximab	40/95 (42.1%)	NR	NR	0
Cravedi et al., 2024 SC [63]	13	13	375	Patient based	Low IgG at 12 months	0 (0%)	0 (0%)	0 (0%)	0
Liu et al., 2024 [64]	76	43	375	Patient based	Low IgG at disease onset	1 (2.3%)	NR	1/1 (100%)	4
Nozu et al., 2024 [65]	6	6	1500	Patient based	Low IgG at last follow-upc	0 (0%)	0 (0%)	0 (0%)	2
Sheng et al., 2025 [66]	24	12	1500	Patient based	Low IgG during rituximab	11/12 (91.7%)	0 (0%)	11/11 (100%)	0
Sinha et al., 2025 [67]	91	91	375–750	Patient based	Low IgG at 18 months	13/91 (14.3%)	NR	NR	6*
Antibody-mediated rejection
Billing et al., 2008 [68]	20	20	375	Patient based	Low IgG at 24 months	6/20 (30.0%)	NR	NR	NR

SC rituximab subcutaneous injection, NR not reported

^*Number of patients

^aMedian follow-up: 9.5 months

^bUnpublished data provided upon request by investigators; at last follow-up (median follow-up 286 days)

^cPersistent hypogammaglobulinemia; 1 followed during rituximab, 5 followed for 2.5 years